Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9190 vs Cisatracurium for Neuromuscular Blockade During General Anesthesia
NCT07446309Phase 2Completed
- Sponsor
- Hengrui
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HRS-9190 in neuromuscular blockade (NMB) (4 arms), sponsored by Hengrui. Primary endpoint: Time from Cessation of Infusion to Recovery of TOFr to 0.9 up to 2 hours. Started Apr 2026; status: completed.
02
Drugs
HRS-9190
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT07446309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446309.